S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.
Chun-Liang LaiYu-Fen WeiTe-Chun HsiaGee-Chen ChangJiun-Ting WuJung-Yueh ChenYuh-Ming ChenPublished in: Asia-Pacific journal of clinical oncology (2019)
This study demonstrated that SP is an effective and safe first-line regimen for Taiwanese patients with advanced NSCLC.